IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY

BACKGROUND: Pediatric glioblastoma (pGBM), despite being relatively rare (incidence rate: 0.5/100,000), are a leading cause of cancer deaths in children with a median overall survival of 9–15 months. In recent years, immunotherapy has emerged as one of the more promising advances in oncology, with i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Chandramohan, Vidyalakshmi, Evangelous, Tyler, Lipp, Eric S, Hora, Bhavna, Bigner, Darell D, McLendon, Roger E, Ashley, David M
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Immunotherapy
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715608/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.381
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak